ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1203

The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis

Jenna Lanz1, Jan Hughes-Austin2, Anna Podolanczuk3, John Kim4, John Austin5, William Robinson6, Ganesh Raghu7, Eric Hoffman8, John Newell Jr8, Jubal Watts Jr9, P. Hrudaya Nath9, Sushilkumar Sonavane10, R. Graham Barr5 and Elana Bernstein1, 1Columbia University, New York, NY, 2University of California, San Diego, San Diego, CA, 3Weill Cornell Medical College, New York, NY, 4University of Virginia School of Medicine, Charlottesville, VA, 5Columbia University Medical Center, New York, NY, 6Stanford University School of Medicine, Palo Alto, CA, 7University of Washington, Seattle, WA, 8University of Iowa, Iowa City, IA, 9University of Alabama at Birmingham, Birmingham, AL, 10Mayo Clinic, Rochester, MN

Meeting: ACR Convergence 2022

Keywords: Anti-CCP, Anti-citrullinated Protein Autoantibodies (ACPAs), Computed tomography (CT), interstitial lung disease, race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: We previously demonstrated a significant association between serum anti-CCP levels and prevalence of interstitial lung abnormalities (ILA) in community-dwelling adults. A greater number of positive anti-citrullinated protein antibodies (ACPAs) has been associated with a greater interstitial lung disease (ILD) extent in adults with RA. The aim of this study was to determine whether greater numbers of positive ACPAs are associated with ILA in community-dwelling adults.

Methods: The Multi-Ethnic Study of Atherosclerosis (MESA) is a multi-center, prospective cohort study of 6814 adults aged 45-84 when recruited in 2000-2002 (Exam 1) from 6 US sites. 29 ACPAs (Table 1) were measured via Bio-Plex bead array in 1949 participants at Exams 2 or 3 (2003-2005) as part of the MESA Abdominal Aortic Calcium ancillary study. 2430 full lung CTs from Exam 5 (2010-2012) had ILA assessments performed by 1 of 5 trained thoracic radiologists. ILA was defined as the presence of ground glass abnormalities, reticular abnormalities, nonemphysematous cysts, honeycombing, and traction bronchiectasis affecting >5% of any lung zone in a non-dependent fashion. A positive ACPA was defined as a titer > 75th percentile. The number of positive ACPA was modeled as the independent continuous variable of interest in a logistic regression model with ILA as the dependent variable, adjusting for age, sex, race/ethnicity, education, cigarette pack-years, and smoking status.

Results: 868 participants had ACPAs measured at Exams 2 or 3 and underwent full lung CT at Exam 5. Median age was 58 (IQR 52-66) years. 50% were female, 42% White, 21% African American, 13% Chinese American, and 24% Hispanic (Table 2). Median number of positive ACPA was 2 (IQR 1-13). 100 participants (11.5%) had ILA on CT. We detected an inverse relationship between number of positive ACPA and odds of ILA in univariate and multivariable models. In the unadjusted model, each 1 unit increase in number of positive ACPA was associated with a 37% decrease in odds of ILA (OR 0.63, 95% CI 0.39 – 1.03, p= 0.06). In a fully adjusted model, each 1 unit increase in number of positive ACPA was associated with an 18% decrease in odds of ILA (OR 0.82, 95% CI 0.67 – 0.98, p= 0.047). In a fully adjusted model, the p-value for interaction between number of positive ACPA and race/ethnicity was 0.04. In fully adjusted models, each 1 unit increase in number of positive ACPA was associated with a 40% decrease in odds of ILA among African American participants (OR 0.60, 95% CI 0.37 – 0.95, p=0.03) and a 42% decrease in odds of ILA among Hispanic participants (OR 0.58, 95% CI 0.37 – 0.90, p=0.02; Table 3). There was no significant association between number of positive ACPA and ILA among White or Chinese American participants.

Conclusion: In this large population-based multi-ethnic study, an expanded ACPA repertoire was associated with a lower burden of ILA on CT, especially among African American and Hispanic participants. This finding was unexpected given the known positive relationship between ILD and an expanded ACPA repertoire in adults with RA. Further studies are necessary to explore whether ACPAs may reduce the risk of ILD in African American and Hispanic adults.

Supporting image 1

Table 1. Anti-Citrullinated Peptide Antibodies Measured at Exam 2 or 3

Supporting image 2

Table 2. Baseline Participant Characteristics

Supporting image 3

Table 3. Association Between Numbers of Positive ACPA and Odds of Interstitial Lung Abnormalities Stratified by Race/Ethnicity


Disclosures: J. Lanz, None; J. Hughes-Austin, None; A. Podolanczuk, Boehringer-Ingelheim, Roche, Imvaria, Regeneron; J. Kim, None; J. Austin, None; W. Robinson, None; G. Raghu, Boehringer-Ingelheim, Bristol-Myers Squibb(BMS), Roche, Genentech; E. Hoffman, None; J. Newell Jr, VIDA, Elsevier Publishing; J. Watts Jr, Boehringer-Ingelheim, Genentech; P. Nath, None; S. Sonavane, None; R. Barr, None; E. Bernstein, Boehringer-Ingelheim, Kadmon, Pfizer.

To cite this abstract in AMA style:

Lanz J, Hughes-Austin J, Podolanczuk A, Kim J, Austin J, Robinson W, Raghu G, Hoffman E, Newell Jr J, Watts Jr J, Nath P, Sonavane S, Barr R, Bernstein E. The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-association-between-anti-citrullinated-peptide-antibodies-and-subclinical-interstitial-lung-disease-in-community-dwelling-adults-the-multi-ethnic-study-of-atherosclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-anti-citrullinated-peptide-antibodies-and-subclinical-interstitial-lung-disease-in-community-dwelling-adults-the-multi-ethnic-study-of-atherosclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology